Macrophages from people with cystic fibrosis (CF) showed multiple defects that may make it harder for them to kill infectious bacteria, a new study reports. The findings also suggest that treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) partially improved CFTR function and corrected some macrophage functions, but was not enough to…